Business Wire

Reprieve Cardiovascular Emerges from Stealth Mode after $42 Million Series A Financing to Bring Intelligent Fluid Management to Heart Failure Patients

MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute ...
Business Wire

Reprieve Cardiovascular Builds Clinical Momentum with Positive Results from FASTR Pilot Trial and FDA Investigational Device Exemption Approval for Pivotal Trial

MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced topline results ...
Morningstar

Reprieve Cardiovascular Announces Publication of FASTR Pilot Trial Results in JACC: Heart Failure

-- Peer-reviewed publication reports faster decongestion with Reprieve Therapy and no increased risk of safety events or worsening kidney function compared to optimal diuretic therapy -- Reprieve ...
Finanznachrichten

Reprieve Cardiovascular, Inc.: Reprieve Cardiovascular Announces Publication of FASTR Pilot Trial Results in JACC: Heart Failure

-- Peer-reviewed publication reports faster decongestion with Reprieve Therapy and no increased risk of safety events or worsening kidney function compared to optimal diuretic therapy -- Reprieve ...